[HTML][HTML] Technical aspects of flow cytometry-based measurable residual disease quantification in acute myeloid leukemia: experience of the European LeukemiaNet …

JM Tettero, S Freeman, V Buecklein, A Venditti… - …, 2022 - journals.lww.com
Measurable residual disease (MRD) quantified by multiparameter flow cytometry (MFC) is a
strong and independent prognostic factor in acute myeloid leukemia (AML). However …

Measurable residual disease in acute myeloid leukemia using flow cytometry: approaches for harmonization/standardization

GJ Schuurhuis, GJ Ossenkoppele… - Expert review of …, 2018 - Taylor & Francis
Introduction: Measurable residual disease (MRD) in acute myeloid leukemia (AML) is a
rapidly evolving area with many institutes embarking on it, both in academic and …

[HTML][HTML] Exploring the efficacy of biosynthesized cupric oxide nanoparticles from Jasminum Sambac flower extract in wastewater treatment: experimental …

G Velmurugan, JS Chohan, K Babu, M Nagaraj… - Desalination and Water …, 2024 - Elsevier
Researchers have shown significant interest in the creation of sustainable green techniques
for synthesising metal oxide nanomaterials in the past few years. Plant-mediated production …

[HTML][HTML] Automated CD34+ cell isolation of peripheral blood stem cell apheresis product

G Spohn, E Wiercinska, D Karpova, M Bunos… - Cytotherapy, 2015 - Elsevier
Background aims Immunomagnetic enrichment of CD34+ hematopoietic “stem” cells (HSCs)
using paramagnetic nanobead coupled CD34 antibody and immunomagnetic extraction …

Cryopreserved hematopoietic stem/progenitor cells stability program-development, current status and recommendations: a brief report from the AABB-ISCT joint …

R Reich-Slotky, LV Vasovic, KJ Land, M Halpenny… - Cytotherapy, 2022 - Elsevier
Abstract Background The AABB-ISCT Joint Working Group Stability Project Team (SPT) was
assigned to roadmap a path toward standardization of cryopreserved hematopoietic …

[HTML][HTML] A Monte Carlo framework for managing biological variability in manufacture of autologous cell therapy from mesenchymal stromal cells therapies

A Picken, J Harriman, A Iftimia-Mander, L Johnson… - Cytotherapy, 2020 - Elsevier
Manufacturing processes for autologous cell therapy need to reproducibly generate in
specification (quality and quantity) clinical product. However, patient variability prevents the …

Does adjunction of autologous osteoblastic cells improve the results of core decompression in early-stage femoral head osteonecrosis? A double-blind, randomized …

M Jayankura, T Thomas, L Seefried… - Clinical Orthopaedics …, 2023 - journals.lww.com
Background Osteonecrosis of the femoral head (ONFH) is a disabling disease that can
ultimately progress to collapse of the femoral head, often resulting in THA. Core …

Automatic generation of alloreactivity-reduced donor lymphocytes and hematopoietic stem cells from the same mobilized apheresis product

E Wiercinska, P Quade-Lyssy, C Hümmer… - Journal of Translational …, 2023 - Springer
Introduction In vitro or in vivo depletion of alloreactive T cells can facilitate haplo-identical
hematopoietic stem cell transplantation (HSCT). Very satisfactory transplant outcomes were …

BAM15 attenuates transportation-induced apoptosis in iPS-differentiated retinal tissue

M Tang, Z Luo, Y Wu, J Zhuang, K Li, D Hu… - Stem Cell Research & …, 2019 - Springer
Background BAM15 is a novel mitochondrial protonophore uncoupler capable of protecting
mammals from acute renal ischemic-reperfusion injury and cold-induced microtubule …

Turning Trash Into Treasure: A Simple Protocol for Human Mesenchymal Stromal Cell Isolation From Used Bone Marrow Collection Kits

Y Anasiz, RK Ozgul, D Uckan‐Cetinkaya - Current Protocols, 2024 - Wiley Online Library
The therapeutic potential of mesenchymal stromal cells (MSCs) has been extensively
investigated in both preclinical and clinical settings. Recent years have witnessed the …